Interstitial Lung Disease Induced by Pazopanib Treatment

Although pneumothorax has been reported to be a major pulmonary adverse event in patients treated with pazopanib, a multikinase inhibitor, drug-induced interstitial lung disease (DILD) has not been reported. A 74-year-old Japanese man who received pazopanib for the treatment of femoral leiomyosarcom...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2017/01/01, Vol.56(1), pp.79-83
Main Authors: Ide, Shotaro, Sakamoto, Noriho, Hara, Shintaro, Hara, Atsuko, Kakugawa, Tomoyuki, Nakamura, Yoichi, Futsuki, Yoji, Izumikawa, Koichi, Ishimatsu, Yuji, Yanagihara, Katsunori, Mukae, Hiroshi
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Asian Continental Ancestry Group
Bronchiectasis
Case Report
Computed tomography
drug-induced interstitial lung disease
Dyspnea
Femoral Artery - physiopathology
Femur
Humans
Internal medicine
interstitial pneumonia
Japan
Leiomyosarcoma - drug therapy
Lung diseases
Lung Diseases, Interstitial - chemically induced
Lung Diseases, Interstitial - drug therapy
Lungs
Male
Medical personnel
Medical treatment
Metastases
molecular target drug
Opacity
pazopanib
pneumonitis
Pneumothorax
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Respiration
Steroids
Steroids - therapeutic use
Sulfonamides - adverse effects
Sulfonamides - therapeutic use
Tomography, X-Ray Computed
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although pneumothorax has been reported to be a major pulmonary adverse event in patients treated with pazopanib, a multikinase inhibitor, drug-induced interstitial lung disease (DILD) has not been reported. A 74-year-old Japanese man who received pazopanib for the treatment of femoral leiomyosarcoma and lung metastasis presented with dyspnea and fatigue. He had mild interstitial pneumonia when pazopanib treatment was initiated. Chest computed tomography revealed progressive bilateral ground-glass opacity (GGO) and traction bronchiectasis. We diagnosed DILD due to pazopanib. The patient's pazopanib treatment was interrupted and a steroid was administered. The symptoms and GGO were improved with treatment. Physicians should be aware of DILD due to pazopanib in patients with pre-existing interstitial lung disease.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.56.7380